These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 15309999)
21. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer. Oehler MK; Sütterlin M; Caffier H Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185 [TBL] [Abstract][Full Text] [Related]
22. [15 years CA-125 antigen: usefulness and limits. Apropos of 3 clinical cases]. Petignat P; Vajda D; Obrist R Praxis (Bern 1994); 1998 Nov; 87(47):1602-5. PubMed ID: 9865132 [TBL] [Abstract][Full Text] [Related]
23. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion]. Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435 [TBL] [Abstract][Full Text] [Related]
24. Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma. Hasholzner U; Baumgartner L; Stieber P; Meier W; Reiter W; Pahl H; Fateh-Moghadam A Int J Cancer; 1996 Aug; 69(4):329-34. PubMed ID: 8797878 [TBL] [Abstract][Full Text] [Related]
26. Differentiation between borderline and benign ovarian tumors: combined analysis of MRI with tumor markers for large cystic masses (≥5 cm). Park SY; Oh YT; Jung DC Acta Radiol; 2016 May; 57(5):633-9. PubMed ID: 26231948 [TBL] [Abstract][Full Text] [Related]
32. [Tumor marker in ovarian cancer]. Komai K; Nishida T Gan To Kagaku Ryoho; 2002 Mar; 29(3):481-6. PubMed ID: 11915744 [TBL] [Abstract][Full Text] [Related]
33. Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours. Lenhard M; Kuemper C; Ditsch N; Diebold J; Stieber P; Friese K; Burges A Clin Chem Lab Med; 2007; 45(5):657-61. PubMed ID: 17484630 [TBL] [Abstract][Full Text] [Related]
34. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670 [TBL] [Abstract][Full Text] [Related]
35. [Tumor markers in epithelial ovarian cancer]. Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857 [TBL] [Abstract][Full Text] [Related]
36. CA 125 in biological fluids. Molina R; Filella X; Jo J; Agusti C; Ballesta AM Int J Biol Markers; 1998; 13(4):224-30. PubMed ID: 10228906 [TBL] [Abstract][Full Text] [Related]
37. [The value of CA 125 determination in the serum of patients with ovarian cancer]. Bartel U; Johannsen B; Elling D Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673 [TBL] [Abstract][Full Text] [Related]
38. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
39. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Le Page C; Ouellet V; Madore J; Hudson TJ; Tonin PN; Provencher DM; Mes-Masson AM Int J Cancer; 2006 Apr; 118(7):1750-8. PubMed ID: 16217764 [TBL] [Abstract][Full Text] [Related]
40. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]